ADAPY (Adaptimmune Therapeutics) Inventories, Finished Goods: $0.49 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Inventories, Finished Goods?

Adaptimmune Therapeutics ADAPY +5.80% Inventories, Finished Goods is $0.49 Mil as of Jun. 2025.

Adaptimmune Therapeutics's quarterly finished goods increased from Dec. 2024 ($0.00 Mil) to Mar. 2025 ($0.24 Mil) and increased from Mar. 2025 ($0.24 Mil) to Jun. 2025 ($0.49 Mil).

Adaptimmune Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Inventories, Finished Goods Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.24 0.49

Adaptimmune Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.49 Mil mean?
Adaptimmune Therapeutics (ADAPY) has a Inventories, Finished Goods of $0.49 Mil as of Jun. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Inventories, Finished Goods too high?
Adaptimmune Therapeutics' current Inventories, Finished Goods is $0.49 Mil.
How does Adaptimmune Therapeutics' Inventories, Finished Goods compare to BCLI and APRE?
Adaptimmune Therapeutics' Inventories, Finished Goods of $0.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Inventories, Finished Goods is $0.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Inventories, Finished Goods of $0.49 Mil. The current Inventories, Finished Goods is $0.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Inventories, Finished Goods is $0.49 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].